EXOZYMES INC (EXOZ) Fundamental Analysis & Valuation

NASDAQ:EXOZ • US4618741098

Current stock price

7.3 USD
+0.09 (+1.25%)
Last:

This EXOZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EXOZ Profitability Analysis

1.1 Basic Checks

  • In the past year EXOZ has reported negative net income.
  • In the past year EXOZ has reported a negative cash flow from operations.
EXOZ Yearly Net Income VS EBIT VS OCF VS FCFEXOZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • EXOZ's Return On Assets of -108.04% is on the low side compared to the rest of the industry. EXOZ is outperformed by 77.07% of its industry peers.
  • EXOZ has a worse Return On Equity (-155.17%) than 63.78% of its industry peers.
Industry RankSector Rank
ROA -108.04%
ROE -155.17%
ROIC N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EXOZ Yearly ROA, ROE, ROICEXOZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 400

1.3 Margins

  • EXOZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EXOZ Yearly Profit, Operating, Gross MarginsEXOZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. EXOZ Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for EXOZ has been increased compared to 1 year ago.
  • EXOZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXOZ Yearly Shares OutstandingEXOZ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
EXOZ Yearly Total Debt VS Total AssetsEXOZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • EXOZ has an Altman-Z score of 8.98. This indicates that EXOZ is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 8.98, EXOZ belongs to the top of the industry, outperforming 80.54% of the companies in the same industry.
  • EXOZ has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of EXOZ (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 8.98
ROIC/WACCN/A
WACCN/A
EXOZ Yearly LT Debt VS Equity VS FCFEXOZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • EXOZ has a Current Ratio of 4.53. This indicates that EXOZ is financially healthy and has no problem in meeting its short term obligations.
  • EXOZ has a Current ratio (4.53) which is in line with its industry peers.
  • EXOZ has a Quick Ratio of 4.53. This indicates that EXOZ is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.53, EXOZ is in line with its industry, outperforming 53.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.53
EXOZ Yearly Current Assets VS Current LiabilitesEXOZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EXOZ Growth Analysis

3.1 Past

  • The earnings per share for EXOZ have decreased strongly by -256.10% in the last year.
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. EXOZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EXOZ. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXOZ Price Earnings VS Forward Price EarningsEXOZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXOZ Per share dataEXOZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EXOZ Dividend Analysis

5.1 Amount

  • EXOZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXOZ Fundamentals: All Metrics, Ratios and Statistics

EXOZYMES INC

NASDAQ:EXOZ (3/13/2026, 8:23:31 PM)

7.3

+0.09 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-08
Inst Owners0.75%
Inst Owner ChangeN/A
Ins Owners24.82%
Ins Owner Change0%
Market Cap61.32M
Revenue(TTM)N/A
Net Income(TTM)-8.34M
AnalystsN/A
Price TargetN/A
Short Float %0.44%
Short Ratio2.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.41
P/tB 11.41
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -108.04%
ROE -155.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 108.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.53
Altman-Z 8.98
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)140.25%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-230.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-505.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-620.26%
OCF growth 3YN/A
OCF growth 5YN/A

EXOZYMES INC / EXOZ Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a fundamental rating of 1 / 10 to EXOZ.


What is the valuation status of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a valuation rating of 0 / 10 to EXOZYMES INC (EXOZ). This can be considered as Overvalued.


What is the profitability of EXOZ stock?

EXOZYMES INC (EXOZ) has a profitability rating of 0 / 10.


Can you provide the financial health for EXOZ stock?

The financial health rating of EXOZYMES INC (EXOZ) is 5 / 10.